<DOC>
	<DOCNO>NCT02294929</DOCNO>
	<brief_summary>Prospective explorative clinical study . The objective ass clinical efficacy pulmonary vein isolation use Arctic Front Advance cryoballoon patient longstanding persistent atrial fibrillation ( AF ) one year follow . 44 subject enrol . Patients longstanding persistent AF , continuous AF duration longer one year , previously undergone AF ablation procedure , symptom relate AF correspond least European Heart Rhythm Association ( EHRA ) score 2 , study . Patients fail least one betablocker class I III antiarrhythmic drug . Excluded congestive heart failure New York Heart Association ( NYHA ) class 3 , leave ventricular ejection fraction &lt; 40 % , leave atrial diameter ≥ 60 mm , significant valvular disease plan cardiac intervention within next 12 month , conventional contraindication AF ablation procedure . Patients screen echocardiography response electrical cardioversion . Following conversion sinus rhythm , amiodarone initiate maintain sinus rhythm . Pulmonary vein isolation perform use Arctic Front Advance cryoballoon ablation catheter . Pulmonary vein conduction block assess circular mapping catheter . All patient subject electroanatomical voltage map sinus rhythm demonstration extent atrial myocardial lesion ablation . Patients follow every third month one year ablation procedure . Arrhythmia monitor follow perform 7 day Holter monitoring 6 , 9 12 month follow , include 12 lead ECG . 12 month follow symptom , EHRA score , quality life . Patients symptomatic recurrence require redo ablation procedure re-studied 8-12 month asymptomatic patient study 12 month follow . Primary end-Point Clinical success base symptom presence AF . Secondary end-Points include freedom AF without antiarrhythmic drug 6 12 month accord 7 day Holter ECG , Rhythm , AF burden , AF profile , Quality Life , Symptoms , Adverse Events , atrial size function , Biomarkers , extent scar tissue , predictive factor freedom AF , complication , hospitalization Health economics .</brief_summary>
	<brief_title>Cryoballoon Ablation Patients With Longstanding Persistent Atrial Fibrillation</brief_title>
	<detailed_description>This prospective explorative clinical study perform one centre . Objective : The objective study assess clinical efficacy pulmonary vein isolation use Arctic Front Advance cryoballoon patient longstanding persistent atrial fibrillation ( AF ) one year follow . 44 subject enrol . Clinical site : Arrhythmia centre Uppsala University Hospital , Uppsala Sweden . Subject population : Patients longstanding persistent AF , continuous AF long duration one year , previously undergone AF ablation procedure , symptom relate AF correspond least EHRA score 2 , study . Atrial fibrillation confirm least 2 consecutive ECG recording past one year support presence AF least one year . Patients fail least betablocker class I III antiarrhythmic drug . In order exclude permanent AF patient , electrical cardioversion conversion sinus rhythm maintain least one hour , require . Excluded patient congestive heart failure New York Heart Association ( NYHA ) class 3 , leave ventricular ejection fraction ( LVEF ) &lt; 40 % , leave atrial diameter ( LA ) ≥ 60 mm , significant valvular disease plan cardiac intervention within next 12 month , conventional medical contraindication AF ablation procedure . Pulmonary vein isolation : Pulmonary vein isolation ( PVI ) perform use Arctic Front Advance cryoballoon ablation catheter . Acute procedural success define electrical isolation pulmonary vein assess entrance exit block , include 20 minute wait time use provocative agent adenosine screen early recurrence PV conduction . Design study : Patients screen echocardiography response electrical cardioversion . Following conversion sinus rhythm , amiodarone initiate order maintain sinus rhythm . After cryoballoon ablation pulmonary vein , PV conduction block assess circular mapping catheter , include wait time provocative agent . All patient subject electro anatomical voltage map sinus rhythm demonstration extent atrial myocardial lesion ablation . Biomarkers include nTproBNP troponin I , reflect myocardial strain destruction , collect baseline different time point procedure . Patients follow every third month one year ablation procedure . Amiodarone withdraw one month ablation procedure . Arrhythmia monitor follow perform 7 day Holter monitoring every third month 6 , 9 12 month follow , include 12 lead ECG . A transthoracic echocardiography repeat 12 month follow assess LA volume contractility . Symptoms , EHRA score , quality life ( QoL ) evaluate . Predictive variable successful outcome/AF recurrence analyse . All patient reinvestigated assessment PV re-conduction use circular mapping catheter , irrespective symptom . Patients symptomatic recurrence require redo ablation procedure re-studied 8-12 month asymptomatic patient study 12 month follow . Primary end-point : Clinical success define - Freedom AF relate symptom , previously ineffective antiarrhythmic drug irrespective presence asymptomatic AF Holter . AF may either absent paroxysmal nature , - Presence AF relate symptom , previously ineffective antiarrhythmic drug , significant symptomatic improvement extent redo procedure novel previously test antiarrhythmic drug desire declared patient symptom questionnaire . Atrial fibrillation may either absent paroxysmal record Holter ECG trace 1 2 procedure 12 month . Secondary end-points : 1 . Complete freedom AF without antiarrhythmic drug 6 12 month 1-2 ablation procedure accord 7 day Holter ECG . 2 . Rhythm ( % subject sinus rhythm , paroxysmal AF persistent AF ) 12 month . 3 . AF burden 7 day Holter 12 month . 4 . AF profile 5 . Assess whether PVI crucial elimination AF patient longstanding persistent AF . Correlation freedom AF/recurrence PV isolation/re-conduction repeat electrophysiological study . 6 . Systemic blood pressure . 7 . Quality Life determine standardized questionnaire ( SF 36 , domains time-points EQ 5D ) . 8 . Symptoms ( Symptoms Severity Questionnaire EHRA Symptom Classification ) . 9 . Incidence , intensity relationship Adverse Events . 10 . Left right atrial size function ( sinus rhythm ) ( echocardiography correct Body Surface area , dPdT ) prior ablation 12 month . 11 . Biomarkers include nTproBNP troponin I , reflect myocardial strain destruction , collect baseline different time point procedure . A biomarker reflect fibrosis brain damage analyse . 12 . Extent scar tissue indicate LA voltage map baseline extent electrical silence around PV postablation . 13 . A subgroup analysis determine whether sinus rhythm obtain AF ablation superior AF regard secondary endpoint include QoL , Symptoms , cardiovascular hospitalization , safety , biomarkers , leave atrial size function , 12 month . 14 . Prediction freedom AF risk variable include LA volume , LA contractility ( strain rate ) , LA intracardiac pressure dpdt , Atrial amplitude analysis AF prior ablation , extent scar tissue assess voltage mapping baseline sinus rhythm , biomarkers , demographic variable ( AF duration , hypertension , ischemic heart disease , diabetes CHADS2VASscore ) . 15 . Catheter related complication . 16 . Cardiovascular hospitalization 17 . Health economics</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . Patients longstanding persistent AF , continuous AF great one year , verify ECG telemetry strip least one year ago , inclusion documentation sinus rhythm . 2 . Atrial fibrillation confirm least 2 consecutive ECG support presence AF least one year . 3 . Patients symptoms correspond least EHRA score 2 . 4 . Patients , previously undergone AF ablation procedure , fail least betablocker class I III antiarrhythmic drug . 1 . Sinus rhythm maintain least 1 minute electrical cardioversion . 2 . Congestive heart failure NYHA class 3 . 3 . LVEF &lt; 35 % secondary AF inadequate rate control , accord judgement investigator . 4 . LA diameter ≥ 55 mm echocardiography . 5 . Prior AF ablation procedure kind . 6 . AF secondary transient correctable abnormality include electrolyte imbalance , trauma , recent surgery , infection , toxic ingestion , uncontrolled thyroid disease well AF trigger uniform supraventricular tachycardia . 7 . Contraindication treatment Warfarin anticoagulant . 8 . Significant valvular disease plan cardiac intervention . 9 . Hypertrophic cardiomyopathy . 10 . Recent cardiac disease state within last 6 month ; unstable angina , acute myocardial infarction , revascularisation procedure , valve disease 11 . Implantable cardioverterdefibrillator ( ICD ) , biventricular pacing device , Dual chamber single chamber pacemaker patient dependent ventricular pace 12 . Patients intraatrial thrombus , tumor , pulmonary embolism another abnormality transseptal catheterization appropriate vascular access preclude . 13 . Renal failure require dialysis abnormality liver function test . 14 . Participant investigational clinical device trial . 15 . Unwilling unable give inform consent inaccessible followup psychological problem might limit compliance . 16 . Active abuse alcohol substance may causative AF and/or might affect compliance .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>catheter ablation</keyword>
	<keyword>cryoballoon</keyword>
</DOC>